Pharmacokinetic Parameters During Pregnancy and Post Partum for Alternative Maraviroc Regimens
| Parameters by Maraviroc Regimen . | 3rd Trimester . | Post Partum . | ||
|---|---|---|---|---|
| Individual1 . | Individual2 . | Individual1 . | Individual2 . | |
| Regimen: 300 mg twice daily (no PI) | ||||
| AUCtau, ng ⋅ mL/h | 911 | 1601 | 995 | NA |
| Cmax, ng/mL | 339 | 349 | 368 | NA |
| tmax, h | 1.92 | 6.03 | 0.83 | NA |
| t½ , h | 8.3 | 3.3 | 12.0 | NA |
| Clast, ng/mL | 30 | 91 | 33 | NA |
| CLss/F, L/h | 329 | 187 | 301 | NA |
| Vdss/F, L | 3934 | 890 | 5227 | NA |
| Cavg, ng/mL | 76 | 133 | 83 | NA |
| 3rd Trimester | Post Partum | |||
| Individual3 | Individual4 | Individual3 | Individual4 | |
| Regimen: 300 mg once daily plus PI | ||||
| AUCtau, ng ⋅ mL/h | 5548 | 10 289 | 7368 | 12 990 |
| Cmax, ng/mL | 906 | 1173 | 835 | 1796 |
| tmax, h | 3.00 | 2.05 | 2.08 | 3.00 |
| t½ , h | 7.9 | 7.2 | 7.9 | 5.1 |
| Clast, ng/mL | 56 | 115 | 74 | 90 |
| CLss/F, L/h | 54 | 29 | 41 | 23 |
| Vdss/F, L | 620 | 303 | 466 | 170 |
| Cavg, ng/mL | 231 | 429 | 307 | 541 |
| 3rd Trimester | Post Partum | |||
| Individual5 | Individual6 | Individual5 | Individual6 | |
| Regimen: 300 mg twice daily plus PI | ||||
| AUCtau, ng ⋅ mL/h | 8400 | 5784 | 15 447 | NA |
| Cmax, ng/mL | 1143 | 1246 | 2161 | NA |
| tmax, h | 4.00 | 2.08 | 4.00 | NA |
| t½ , h | 5.1 | 4.0 | 3.7 | NA |
| Clast, ng/mL | 314 | 136 | 482 | NA |
| CLss/F, L/h | 36 | 26 | 19 | NA |
| Vdss/F, L | 264 | 148 | 104 | NA |
| Cavg, ng/mL | 700 | 482 | 1287 | NA |
| Parameters by Maraviroc Regimen . | 3rd Trimester . | Post Partum . | ||
|---|---|---|---|---|
| Individual1 . | Individual2 . | Individual1 . | Individual2 . | |
| Regimen: 300 mg twice daily (no PI) | ||||
| AUCtau, ng ⋅ mL/h | 911 | 1601 | 995 | NA |
| Cmax, ng/mL | 339 | 349 | 368 | NA |
| tmax, h | 1.92 | 6.03 | 0.83 | NA |
| t½ , h | 8.3 | 3.3 | 12.0 | NA |
| Clast, ng/mL | 30 | 91 | 33 | NA |
| CLss/F, L/h | 329 | 187 | 301 | NA |
| Vdss/F, L | 3934 | 890 | 5227 | NA |
| Cavg, ng/mL | 76 | 133 | 83 | NA |
| 3rd Trimester | Post Partum | |||
| Individual3 | Individual4 | Individual3 | Individual4 | |
| Regimen: 300 mg once daily plus PI | ||||
| AUCtau, ng ⋅ mL/h | 5548 | 10 289 | 7368 | 12 990 |
| Cmax, ng/mL | 906 | 1173 | 835 | 1796 |
| tmax, h | 3.00 | 2.05 | 2.08 | 3.00 |
| t½ , h | 7.9 | 7.2 | 7.9 | 5.1 |
| Clast, ng/mL | 56 | 115 | 74 | 90 |
| CLss/F, L/h | 54 | 29 | 41 | 23 |
| Vdss/F, L | 620 | 303 | 466 | 170 |
| Cavg, ng/mL | 231 | 429 | 307 | 541 |
| 3rd Trimester | Post Partum | |||
| Individual5 | Individual6 | Individual5 | Individual6 | |
| Regimen: 300 mg twice daily plus PI | ||||
| AUCtau, ng ⋅ mL/h | 8400 | 5784 | 15 447 | NA |
| Cmax, ng/mL | 1143 | 1246 | 2161 | NA |
| tmax, h | 4.00 | 2.08 | 4.00 | NA |
| t½ , h | 5.1 | 4.0 | 3.7 | NA |
| Clast, ng/mL | 314 | 136 | 482 | NA |
| CLss/F, L/h | 36 | 26 | 19 | NA |
| Vdss/F, L | 264 | 148 | 104 | NA |
| Cavg, ng/mL | 700 | 482 | 1287 | NA |
Abbreviations: AUCtau, area under the curve over a dosing period; Cavg, average concentration; CI, confidence interval; CL, clearance; Clast, concentration at last time point (12 or 24 hours after dosing); Cmax, maximum concentration; F, oral bioavailability; NA, not available; PI, protease inhibitor; t½, half-life; tmax, time of maximum concentration; Vd, apparent volume of distribution.
Pharmacokinetic Parameters During Pregnancy and Post Partum for Alternative Maraviroc Regimens
| Parameters by Maraviroc Regimen . | 3rd Trimester . | Post Partum . | ||
|---|---|---|---|---|
| Individual1 . | Individual2 . | Individual1 . | Individual2 . | |
| Regimen: 300 mg twice daily (no PI) | ||||
| AUCtau, ng ⋅ mL/h | 911 | 1601 | 995 | NA |
| Cmax, ng/mL | 339 | 349 | 368 | NA |
| tmax, h | 1.92 | 6.03 | 0.83 | NA |
| t½ , h | 8.3 | 3.3 | 12.0 | NA |
| Clast, ng/mL | 30 | 91 | 33 | NA |
| CLss/F, L/h | 329 | 187 | 301 | NA |
| Vdss/F, L | 3934 | 890 | 5227 | NA |
| Cavg, ng/mL | 76 | 133 | 83 | NA |
| 3rd Trimester | Post Partum | |||
| Individual3 | Individual4 | Individual3 | Individual4 | |
| Regimen: 300 mg once daily plus PI | ||||
| AUCtau, ng ⋅ mL/h | 5548 | 10 289 | 7368 | 12 990 |
| Cmax, ng/mL | 906 | 1173 | 835 | 1796 |
| tmax, h | 3.00 | 2.05 | 2.08 | 3.00 |
| t½ , h | 7.9 | 7.2 | 7.9 | 5.1 |
| Clast, ng/mL | 56 | 115 | 74 | 90 |
| CLss/F, L/h | 54 | 29 | 41 | 23 |
| Vdss/F, L | 620 | 303 | 466 | 170 |
| Cavg, ng/mL | 231 | 429 | 307 | 541 |
| 3rd Trimester | Post Partum | |||
| Individual5 | Individual6 | Individual5 | Individual6 | |
| Regimen: 300 mg twice daily plus PI | ||||
| AUCtau, ng ⋅ mL/h | 8400 | 5784 | 15 447 | NA |
| Cmax, ng/mL | 1143 | 1246 | 2161 | NA |
| tmax, h | 4.00 | 2.08 | 4.00 | NA |
| t½ , h | 5.1 | 4.0 | 3.7 | NA |
| Clast, ng/mL | 314 | 136 | 482 | NA |
| CLss/F, L/h | 36 | 26 | 19 | NA |
| Vdss/F, L | 264 | 148 | 104 | NA |
| Cavg, ng/mL | 700 | 482 | 1287 | NA |
| Parameters by Maraviroc Regimen . | 3rd Trimester . | Post Partum . | ||
|---|---|---|---|---|
| Individual1 . | Individual2 . | Individual1 . | Individual2 . | |
| Regimen: 300 mg twice daily (no PI) | ||||
| AUCtau, ng ⋅ mL/h | 911 | 1601 | 995 | NA |
| Cmax, ng/mL | 339 | 349 | 368 | NA |
| tmax, h | 1.92 | 6.03 | 0.83 | NA |
| t½ , h | 8.3 | 3.3 | 12.0 | NA |
| Clast, ng/mL | 30 | 91 | 33 | NA |
| CLss/F, L/h | 329 | 187 | 301 | NA |
| Vdss/F, L | 3934 | 890 | 5227 | NA |
| Cavg, ng/mL | 76 | 133 | 83 | NA |
| 3rd Trimester | Post Partum | |||
| Individual3 | Individual4 | Individual3 | Individual4 | |
| Regimen: 300 mg once daily plus PI | ||||
| AUCtau, ng ⋅ mL/h | 5548 | 10 289 | 7368 | 12 990 |
| Cmax, ng/mL | 906 | 1173 | 835 | 1796 |
| tmax, h | 3.00 | 2.05 | 2.08 | 3.00 |
| t½ , h | 7.9 | 7.2 | 7.9 | 5.1 |
| Clast, ng/mL | 56 | 115 | 74 | 90 |
| CLss/F, L/h | 54 | 29 | 41 | 23 |
| Vdss/F, L | 620 | 303 | 466 | 170 |
| Cavg, ng/mL | 231 | 429 | 307 | 541 |
| 3rd Trimester | Post Partum | |||
| Individual5 | Individual6 | Individual5 | Individual6 | |
| Regimen: 300 mg twice daily plus PI | ||||
| AUCtau, ng ⋅ mL/h | 8400 | 5784 | 15 447 | NA |
| Cmax, ng/mL | 1143 | 1246 | 2161 | NA |
| tmax, h | 4.00 | 2.08 | 4.00 | NA |
| t½ , h | 5.1 | 4.0 | 3.7 | NA |
| Clast, ng/mL | 314 | 136 | 482 | NA |
| CLss/F, L/h | 36 | 26 | 19 | NA |
| Vdss/F, L | 264 | 148 | 104 | NA |
| Cavg, ng/mL | 700 | 482 | 1287 | NA |
Abbreviations: AUCtau, area under the curve over a dosing period; Cavg, average concentration; CI, confidence interval; CL, clearance; Clast, concentration at last time point (12 or 24 hours after dosing); Cmax, maximum concentration; F, oral bioavailability; NA, not available; PI, protease inhibitor; t½, half-life; tmax, time of maximum concentration; Vd, apparent volume of distribution.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
